“We tend to think of this disease as a children’s disease, but our data show that’s not the case,” said the study’s lead author Dr. Zelma C. Chiesa Fuxench, in a press release. “Our findings show this disease affects seven per cent of the population, far more than other inflammatory conditions like psoriasis, which only affects about three per cent. "
"Our study found there are significant differences in the skin of people with AD than in those without the condition. Furthermore, we found African Americans with AD have more inflammation than European Americans with the condition," said Dr. Emma Guttman-Yassky.
To mark the event, EFA has also released a new report titled Itching for Life: Quality of Life and costs for people living with severe atopic eczema in Europe. The report highlights the reality of AD, which come from the largest-ever Quality of Life survey about the condition.
“By applying bacteria from a healthy source to the skin of people with atopic dermatitis, we aim to alter the skin microbiome in a way that will relieve symptoms and free people from the burden of constant treatment,” said the trial’s principal investigator, NIAID’s Dr. Ian Myles.
Specifically, these factors include genetic predisposition to skin barrier defects, use of infant cleansing wipes that leave soap residue, skin exposure to allergens such as dust, and skin exposure to food allergens from caregivers.